TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Prognostic Value of Aβ Imaging in NPH Prior to Shunt Placement

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 60.~2. Visual and auditory acuity adequate for neuropsychological testing.~3. Completed six grades of education or has a good work history (sufficient to exclude mental retardation).~4. Must speak English fluently.~5. Willing to undergo one Amyloid imaging PET scan.~6. Agrees to at least one lumbar puncture for the collection of CSF.~7. Must agree to return for a Month 3 and Month 12 visit.~8. Participant, who in the opinion of the investigator, can tolerate the PET scan procedures~Exclusion Criteria:~1. History of schizophrenia (DSM IV criteria).~2. History of alcohol or substance abuse or dependence within the past 2 years (DSM IV criteria).~3. Participation in clinical studies involving neuropsychological measures being collected more than one time per year.~4. Exclusion for amyloid imaging with 18F -AV-45: Current or recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the participant in any given year would exceed the limits of annual and total dose commitment set forth in the US Code of Federal Regulations (CFR) Title 21 Section 361.1.~5. Clinically significant hepatic, renal, pulmonary, metabolic, or endocrine disturbances as indicated by history, which in the opinion of the investigator might pose a potential safety risk to the participant?~6. Current clinically significant cardiovascular disease, including one or more of:~   * cardiac surgery or myocardial infarction within the last 4 weeks;~  * unstable angina;~  * acute decompensated congestive heart failure or class IV heart failure

- Gender: ALL
- Minimum Age: 60 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Florbetapir +ve NPH patients (Type: None): Florbetapir +ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months
- Florbetapir -ve patients (Type: None): Florbetapir -ve patients will have neuropsychology tests prior to surgery and then at 3 and 12 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed stage IV adrenal gland carcinoma that is unlikely to respond to existing therapy and for which no curative therapy exists~* Measurable disease by MRI or CT scan~* Tumor must be greater than 2 cm at the largest diameter for the lymph nodes located in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in the largest diameter for other localizations~PATIENT CHARACTERISTICS:~Age:~* 6 months and over~Performance status:~* Karnofsky 60-100%~Life expectancy:~* At least 2 months~Hematopoietic:~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~Hepatic:~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~Renal:~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~Cardiovascular:~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~Pulmonary:~* No severe lung disease~Other:~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections or fever~* No other concurrent serious disease~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~Chemotherapy:~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* No concurrent antineoplastic agents~Endocrine therapy:~* Concurrent corticosteroids allowed~Radiotherapy:~* At least 8 weeks since prior radiotherapy and recovered~Surgery:~* Recovered from any prior operative procedure~Other:~* No prior antineoplaston therapy~* Prior cytodifferentiating agent allowed

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplaston therapy (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of an Incontinence Product

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* English speaking/reading adults, age ≥ 18 years~* Incontinent (fecal, urine, or dual incontinence)~* Patients with dual incontinence who require use of a fecal management system (but no urinary catheter)~* Absence of skin irritation, breakdown, and pressure injuries present in the buttocks, sacrum, and/or perineal areas at the time of enrollment; minor irritation may be acceptable at the discretion of the Study Investigator~* Willing and able to provide written informed consent or legal authorized representative is willing and able to provide written informed consent~Exclusion Criteria:~* Presence of skin irritation and/or breakdown including but not limited to IAD or pressure injuries present in the buttocks, sacrum, and/or perineal areas at the time of enrollment; minor irritation may be acceptable at the discretion of the study Investigator~* Require use of an absorbent undergarment (e.g. Depends) or catheter as the primary incontinence management strategy~* Is considered to be near death or requires hospice care

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Phase 1 (Type: None): Subjects will use the incontinence pad with incontinence detection notifications turned on
- Phase 2 (Type: None): Subjects will use the incontinence pad with incontinence notification turned off

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Mindfulness/Meditation on Post-operative Pain and Opioid Consumption

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years and older~* Status post shoulder arthroscopy for rotator cuff repair, biceps tendinopathy, and/or Mumford Procedure~Exclusion Criteria:~* Less than 18 years old~* Patients undergoing a simultaneous arthroscopic procedure that is not in the inclusion criteria.~* History of shoulder osteoarthritis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- control (CON) (Type: ACTIVE_COMPARATOR): will receive the usual standard of care post-operative pain pills for the involved shoulder (Control Group)
- Mindfulness/Meditation (MM) (Type: EXPERIMENTAL): will receive the usual standard of care post-operative pain pills for the involved shoulder with the addition of access to the Headspace application for mindfulness/meditation (Mindfulness/Meditation Group)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Plasma Concentration of Biological Markers in Placenta Accreta Spectrum

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age 18 - to 45-years old, inclusive~* Suspected or confirmed PAS or phenotypically matched controls~* Delivery by cesarean section~* Gestational age greater than 28 weeks~* Singleton pregnancy~Exclusion Criteria:~* Intrauterine fetal demise,~* Severe fetal anomalies (infant not expected to survive)~* Emergent cesarean delivery

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- Placenta accreta spectrum (Type: None): Mother-infant dyads with suspected or confirmed diagnosis of placenta accreta spectrum
- Phenotypically-matched controlled group (Type: None): Mother-infant dyads admitted for delivery without placenta accreta spectrum

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metatarsophalangeal Arthrodesis of the Hallux

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient undergoing isolated first ray surgery (M1 only) of hallux valgus, hallux varus or hallux rigidus by percutaneous or conventional approach;~* Patient who can benefit from first-line arthrodesis using a dorsal plate or large-diameter screw;~* Patient able to understand information related to the study and complete quality of life questionnaires;~* Patient accepting study follow-up visits;~* Patient having been informed and agreeing to participate in the study.~Exclusion Criteria:~* Pregnant or breastfeeding women;~* Patient undergoing lateral ray surgery;~* Patient undergoing revision arthrodesis;~* Patient with a loss of bone substance requiring a graft;~* Patient suffering from chronic inflammatory disease;~* Patient treated with long-term immunosuppressive or corticosteroid treatments;~* Patient under guardianship or curatorship, or under a regime of deprivation of liberty.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metatarsophalangeal arthrodesis of the hallux with large diameter screws (Type: None): Patient who can benefit from first-line arthrodesis using large-diameter screws
- Metatarsophalangeal arthrodesis of the hallux by plate (Type: None): Patient who can benefit from a first intention arthrodesis by dorsal plate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Transvaginal Tape (TVT) Secur Versus TVT Randomised Controlled Trial (RCT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Women with stress incontinence, defined as leaking with increased abdominal pressure~* Eligible for both types of surgery~Exclusion Criteria:~Women who:~* Have vaginal prolapse requiring surgical repair~* Have had previous incontinence surgery~* Have overactive bladder or incontinence is caused only by bladder overflow~* Intend to have further children~* Have Alzheimer's or Parkinson's disease, progressive neurological disease such as multiple sclerosis, or are immunocompromised~* Are unable to understand English~* Will be unavailable for follow-up

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TVT Secur surgical device (Type: EXPERIMENTAL): Single incision tape device
- TVT surgical device (Type: ACTIVE_COMPARATOR): Usual care retropubic tape device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Chiropractic Treatment on Infantile Colic A Randomized, Controlled Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age: 2-10 weeks.~* Minimum crying and fussing: three hours per day, three days per week.~Exclusion criteria:~* Known disease.~* Unsatisfying weight gain.~* Psychological or developmental compromise.~* Contraindications for chiropractic treatment.

- Gender: ALL
- Minimum Age: 2 Weeks
- Maximum Age: 10 Weeks
- Healthy Volunteers: f

Study Arms:
- Chiropractic treatment (Type: EXPERIMENTAL): Manipulation and/or mobilisation
- Visit without active treatment (Type: PLACEBO_COMPARATOR): The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Trial of the Effect of Preoperative Forced-air Warming on Perioperative Body Temperature Following Neuraxial Anesthesia in Total Hip Arthroplasty Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing total hip arthroplasty under neuraxial anesthesia,~* age 55-85,~* BMI 18-40~Exclusion Criteria:~* allergy to local anesthetics,~* patients electing to have general anesthesia for their total hip arthroplasty,~* pregnancy,~* prisoners,~* patients unable to give informed consent,~* English as a second language,~* active infectious or febrile illness (measured temperature \> 37.5 degrees Celsius).

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Pre-Warming (Type: EXPERIMENTAL): None
- Control (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Laparoscopic to Vaginal Surgical Repair for Uterine Prolapse

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with primary symptomatic uterine prolapse~* ≥ 18 years of age~* Considering pelvic reconstructive surgery~Exclusion Criteria:~* Unwillingness to be randomized to one of two surgical approaches~* Pregnant or planning to maintain their future fertility~* Unable to have general anesthesia~* Currently undergoing chemotherapy OR has current or history of pelvic radiation~* Previous adverse reaction to synthetic mesh~* Recent history of abnormal paps (past 10 years)~* Cervical or uterine cancers~* Previous hysterectomy~* Previous central vault or uterine prolapse repair~* Uterus ≥ 14 weeks size~* Uterine cancer~* History of significant pelvic adhesive disease~* Elongated cervix (length D to C \> 6cm)~* Fibroid ≥ 7cm~* Post menopausal with enlarged uterus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Laparoscopic Repair (Type: ACTIVE_COMPARATOR): Laparoscopic supracervical hysterectomy with sacropexy
- Vaginal Repair (Type: ACTIVE_COMPARATOR): Vaginal hysterectomy with uterosacral colposuspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Yoga to Improve Physical Function and Maximal Walking Distance Among Patients With Peripheral Arterial Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 40~* Diagnosis of lower extremity PAD (defined as a documented ankle-brachial index of \< 0.9)~* Do less than 150 minutes of exercise per week~* Competent to give informed consent~Exclusion Criteria:~* Life expectancy under 1 year~* Pregnancy~* Co-morbidities which limit physical activity to a severe degree (unable to walk at least a block)~* Signs of critical limb ischemia and/or planned revascularization in the next 12-months~* Recent CVD event (\< 3 months) including stroke/transient ischemic attack (TIA), myocardial infarction (MI), unstable angina (UA), percutaneous coronary intervention (PCI)/coronary artery bypass grafting (CABG), or severe valve disease, congenital heart disease, complex arrhythmias (untreated), NYHA class III-IV heart failure~* Recent or current enrollment in formal exercise or yoga program~* Psychiatric disorder, which limits subjects ability to follow the study protocol~* Current substance abuse~* Non-English speaking

- Gender: ALL
- Minimum Age: 41 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Yoga intervention (Type: EXPERIMENTAL): None
- Wait list control (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sleep Apnea in Early to Mid-Stage Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of Alzheimer-type dementia confirmed by the study's memory specialist.~* MMS comprised between 20 and 28 (inclusive)~* One main caregiver with full mental capacity, living under the same roof, present at all medical visits~* Patient covered by compulsory health insurance~* Patient signed the informed consent form~Exclusion Criteria:~* Prior diagnosis of sleep apnea or patients already benefitting from respiratory assistance equipment- History of COPD (Chronic Obstructive Pulmonary Disease), treated with bronchodilators or corticoids~* Patients with severe heart failure (stages III and IV of the NYHA Functional Classification)~* Patients with a recent history of stroke or myocardial infarction (within the last three months)~* Recently initiated or modified anticholinergic treatment (within the last two months)~* Patients under guardianship~* Behavioral disorders (pacing, agitation)~* Patients with severe dementia~* Patient with potentially low tolerance to treatment (latex allergies, claustrophobia, prior CPAP treatment which was badly tolerated)~* Serious bullous lung disease~* Pneumothorax~* Arterial hypotension~* Dehydration~* Cerebrospinal fluid effusion, recent concussion, or cranial surgery

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OSAS + (Type: None): Patient with obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography
- OSAS - (Type: None): Patient without obstructive sleep apnea syndrome (OSAS)detected at the inclusion visit by a polysomnography

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Analyze the Effects of EBI OsteoGen™ on the Surgical Reconstruction of Tibia Non-unions

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of a tibia nonunion.~2. Male or female between ages of 18 and 75 years old, inclusive~Exclusion Criteria:~1. Subject has open wounds or underlying osteomyelitis.~2. Subject has associated multiple traumas, and/or fractures that are not anatomically reduced or lose reduction at later time points.~3. If female, subject is pregnant, plans on becoming pregnant during the duration of this clinical outcomes collection study or lactating.~4. Subject has an implanted unipolar pacemaker.~5. Subject has active cancer.~6. Subject has severe peripheral vascular disease (ABI \<0.4)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 1 - standard films (Type: None): Tibia reconstruction surgery with OsteoGen™ with standard radiographs
- 2 - Standard films plus CT (Type: None): Tibia reconstruction surgery with OsteoGen™ with standard radiographs and additional CT scan at 10 and 18 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues